ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA filed a Form 6-K for June 2021. The filing reports the results of the company’s annual general meeting held on June 10, 2021, and was signed on June 11, 2021. The company is a foreign private issuer that files annual reports on Form 20-F.
Financial metrics and capital structure
- Shareholders approved the 2020 Management Report, annual financial statements, consolidated financial statements and auditors’ reports.
- The company reported a 2020 net loss of CHF 203.4 million, which was carried forward.
- Total accumulated loss carried forward after the appropriation was CHF 645.3 million.
- The filing does not provide revenue, cash flow, margins, debt, cash balances, liquidity measures or additional operating metrics.
Material changes and corporate actions
- Shareholders approved an increase and renewal of authorized share capital by CHF 1.17 million through an amendment to Article 4a of the Articles of Association.
- The maximum size of the Board of Directors was increased to 12 members.
- All incumbent directors were re-elected for terms ending at completion of the 2022 annual general meeting.
- Viviane Monges, a former senior finance executive at Nestlé, Galderma, Novartis and Wyeth, was elected as a new director.
- Monges joined the Audit Committee on June 10, 2021, after Stephen Evans-Freke resigned from that committee on May 12, 2021. The Board determined that Monges is independent under Exchange Act Rule 10A-3, financially literate and an audit committee financial expert.
- PricewaterhouseCoopers SA was re-elected as statutory auditor for fiscal year 2021.
- Martin Habs was re-elected as independent proxy through the 2022 annual general meeting.
Compensation, outlook and risks
- Shareholders approved maximum aggregate compensation of USD 5.0 million for the Board of Directors for the period from the 2021 annual general meeting through the 2022 annual general meeting.
- Shareholders approved maximum aggregate fixed compensation of USD 7.1 million for the Executive Committee for fiscal 2022.
- Shareholders approved maximum aggregate variable compensation of USD 26.5 million for the Executive Committee for fiscal 2021.
- The filing contains no new revenue guidance, clinical or commercial outlook, financing forecast, contingencies or detailed risk commentary.
- The approved increase in authorized share capital provides additional potential equity issuance capacity; the filing does not state that shares were issued in connection with the meeting.
Key facts investors should verify
- Review the company’s 2020 Form 20-F for the underlying financial statements, cash runway, debt, liquidity and operating results.
- Assess the potential dilution implications of the CHF 1.17 million increase and renewal of authorized share capital.
- Monitor the composition and independence of the Board and Audit Committee, including Viviane Monges’ role as audit committee financial expert.
- Compare the approved compensation limits with subsequent actual compensation disclosures.
- Confirm the amended Articles of Association filed as Exhibit 99.1 and determine whether additional governance or capital provisions were changed.